Research programme: anti-inflammatory polysaccharides - Verona

Drug Profile

Research programme: anti-inflammatory polysaccharides - Verona

Alternative Names: NAIPS

Latest Information Update: 22 Apr 2013

Price : $50

At a glance

  • Originator Verona Pharma
  • Developer GlycoMar; Verona Pharma
  • Class Polysaccharides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Research Allergic rhinitis; Asthma

Most Recent Events

  • 22 Apr 2013 Early research is ongoing in United Kingdom
  • 18 Jun 2008 Early research in Asthma in United Kingdom (unspecified route)
  • 18 Jun 2008 Early research in Allergic rhinitis in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top